LBCTR2021014651
Not yet recruiting
Phase 3
Managing Endothelial Dysfunction in COVID-19: A Randomized Clinical Trial at the Lebanese American University Medical Center- Rizk Hospital - MEDIC-LAUMCRH
AUMCRH0 sites80 target enrollmentFebruary 8, 2021
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- COVID-19 and the cardiovascular systemWe will aim at treating endothelial dysfunction caused by covid -19 virus by an endothelial protocol to try to improve the patient's outcome
- Sponsor
- AUMCRH
- Enrollment
- 80
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •INCLUSION CRITERIA: Firstly, participants must be in\-patient adults 18
- •years of age and above. Secondly, having PCR\-confirmed COVID\-19
- •classified as mild, moderate or severe disease as per the FDA and
- •admitted to the hospital for inpatient treatment as per the standard
- •of care, with mild being a positive testing by standard RT\-PCR assay or
- •equivalent test and symptoms of mild illness with COVID\-19 that
- •could include fever, cough, sore throat, malaise, headache, muscle
- •pain, gastrointestinal symptoms, without shortness of breath or
- •dyspnea. No clinical signs indicative of Moderate, Severe, or Critical
- •Severity. Moderate defined as positive testing by standard RT\-PCR
Exclusion Criteria
- •EXCLUSION CRITERIA:
- •Patients unable to tolerate oral
- •medications. Patients who are already on beta\-blockers,
- •statins or Nicorandil, PDE5 inhibitors, Riociguat.. In addition to
- •those with shock as defined by SBP\<90 for more than 30
- •minutes not responding to IV fluids with evidence of end organ
- •damage. Patients with severe bradycardia (\<50 bpm) and heart
- •block greater than first\-degree (except in patients with a
- •functioning artificial pacemaker) should be definitely excluded,
- •along with those who suffer from decompensated heart failure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Endothelial Dysfunction during The COVID-19 follow-up: TUN-EndCOV studyCirculatory SystemRespiratoryCardiologyPACTR202102867544936600
Unknown
Phase 3
Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMCCovid19NCT04631536Lebanese American University Medical Center42
Unknown
Phase 3
Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRHCovid19Endothelial DysfunctionNCT04813471Lebanese American University Medical Center70
Completed
Not Applicable
Effect of COVID-19 on Endothelial FunctionCOVID-19Endothelial DysfunctionNCT05500560University Hospital of Patras44
Active, not recruiting
Phase 1
A prospective, randomised, placebo-controlled, investigator-initiated study of the effect of Sulodexide on endothelial protection in convalescent COVID-19 patients.EUCTR2022-001958-36-HUCorporativo de Servicios Médicos Especializados S.A de C.V V (Centro Médico del Noroeste)200